Literature DB >> 14738432

Newborn screening for sickle cell disease in Brazil: the Campinas experience.

S Brandelise1, V Pinheiro, C S Gabetta, I Hambleton, B Serjeant, G Serjeant.   

Abstract

Newborn screening for sickle cell disease commenced in 1992 in Sao Paulo State and by the end of 2000, the programme covered 78 institutions in 36 municipalities with the screening of 281,884 babies. Initially based on liquid cord blood samples, these are being replaced by dried filter paper capillary samples to ease handling and avoid diagnostic confusion from maternal contamination. The prevalence of sickle cell trait (2.0%) and HbC trait (0.6%) increased significantly between 1996 and 2000, apparently because of improved detection rather than the later introduction of institutions serving populations with higher trait frequencies. There were 29 babies with homozygous sickle cell SS disease and 26 with sickle cell-haemoglobin C (SC) disease, the latter significantly exceeding expectation and possibly attributable to a nonrandom selection of partners. Sickle cell-beta thalassaemia syndromes were proportionately more common than in Jamaica, and it is possible that this results from interaction with other Brazilian populations carrying higher beta thalassaemia gene frequencies. The frequency of abnormal haemoglobins in this population is lower than in Jamaica, but clinically significant sickle cell disease occurred once in every 5527 births, comparable with the frequencies of other significant inborn errors of metabolism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14738432     DOI: 10.1111/j.0141-9854.2003.00576.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  8 in total

1.  Hemoglobin sickle cell disease in Brazil.

Authors:  Ana Carolina Cabañas-Pedro; Josefina A P Braga; Roberta F Camilo-Araújo; Ana I M Silva; Perla Vicari; Maria Figueiredo
Journal:  Haematologica       Date:  2013-01       Impact factor: 9.941

2.  Critical analysis of the neonatal screening program for hemoglobinopathies.

Authors:  Raphaela Martins Muniz Moreira; Isabeth da Fonseca Estevão; Débora Gusmão Melo
Journal:  Rev Bras Hematol Hemoter       Date:  2011

3.  Prevalence of sickle cell disease and sickle cell trait in national neonatal screening studies.

Authors:  Luciana Garcia Lervolino; Paulo Eduardo Almeida Baldin; Silvia Miguéis Picado; Karina Barreto Calil; Ana Amélia Viel; Luiz Alexandre Freixo Campos
Journal:  Rev Bras Hematol Hemoter       Date:  2011

4.  Sickle cell disease: from the beginning until it was recognized as a public health disease.

Authors:  Paulo Cesar Naoum
Journal:  Rev Bras Hematol Hemoter       Date:  2011

5.  Newborn screening in Latin America at the beginning of the 21st century.

Authors:  G J C Borrajo
Journal:  J Inherit Metab Dis       Date:  2007-08-14       Impact factor: 4.982

6.  Enablers and barriers to newborn screening for sickle cell disease in Africa: results from a qualitative study involving programmes in six countries.

Authors:  Natasha M Archer; Baba Inusa; Julie Makani; Siana Nkya; Léon Tshilolo; Venee N Tubman; Patrick T McGann; Emmanuela Eusebio Ambrose; Natalie Henrich; Jonathan Spector; Kwaku Ohene-Frempong
Journal:  BMJ Open       Date:  2022-03-09       Impact factor: 2.692

7.  Guidelines on neonatal screening and painful vaso-occlusive crisis in sickle cell disease: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular: Project guidelines: Associação Médica Brasileira - 2016.

Authors:  Josefina Aparecida Pellegrini Braga; Mônica Pinheiro de Almeida Veríssimo; Sara Teresinha Olalla Saad; Rodolfo Delfini Cançado; Sandra Regina Loggetto
Journal:  Rev Bras Hematol Hemoter       Date:  2016-04-08

8.  Feasibility and acceptability of early infant screening for sickle cell disease in Lagos, Nigeria-A pilot study.

Authors:  Esther O Oluwole; Titilope A Adeyemo; Gbemisola E Osanyin; Oluwakemi O Odukoya; Phyllis J Kanki; Bosede B Afolabi
Journal:  PLoS One       Date:  2020-12-03       Impact factor: 3.752

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.